RO 0282425Alternative Names: MC4 agonist; RO0282425
Latest Information Update: 04 Mar 2010
At a glance
- Originator Roche
- Mechanism of Action Melanocortin type 4 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 01 Sep 2005 Phase-II clinical trials in Erectile dysfunction in USA (unspecified route)